MedTrace Logo

Novel Approaches for Improving Vascular Function in Veterans With HFpEF

NCT06312748 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2026-04-23

No results posted yet for this study

Summary

This project will evaluate the impact of L-Citrulline, tetrahydrobiopterin (BH4), and atorvastatin administration on physical capacity and vascular function in Veterans with heart failure with preserved ejection fraction (HFpEF).

Conditions

Interventions

DRUG

L-Citrulline

100 mg tablet

DRUG

Placebo for L-Citrulline

L-Citrulline-matched Placebo tablet

DRUG

BH4

10mg/kg

DRUG

Placebo for BH4

BH4-matched Placebo

DRUG

Atorvastatin

10 mg tablet

DRUG

Placebo for Atorvastatin

Atorvastatin-matched Placebo

Sponsors & Collaborators

Principal Investigators

  • David W. Wray, PhD · VA Salt Lake City Health Care System, Salt Lake City, UT

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-19
Primary Completion
2028-09-30
Completion
2030-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06312748 on ClinicalTrials.gov